Trial Profile
A Phase I Trial of Peptide-Based Glioma Vaccine IMA950 in Patients With Glioblastoma (GBM)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 30 Dec 2021
Price :
$35
*
At a glance
- Drugs IMA 950 (Primary) ; Cyclophosphamide; Granulocyte macrophage colony stimulating factor; Imiquimod; Subunit vaccines
- Indications Glioblastoma
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Sponsors Immatics N.V.
- 14 May 2014 Status changed from active, no longer recruiting to discontinued, as per ClinicalTrials.gov record.
- 14 May 2014 Status changed from active, no longer recruiting to discontinued, as per ClinicalTrials.gov record.
- 14 Apr 2014 Planned End Date changed from 1 Mar 2014 to 1 Apr 2014, as per ClinicalTrials.gov record.